255 unknown, 82 recruiting, 55 completed, 37 not yet recruiting. 344 Phase 2, 64 Phase 1, 61 Phase 3, 29 Not applicable, 2 Early Phase 1.
Follow camrelizumab: new trials by email Literature Review of camrelizumab trials Research Report on camrelizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer H101, Camrelizumab - Pancreatic Cancer | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2025-08-07 |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin - ESCC | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 33 | 2026-09-10 | 2026-09-09 |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab) - Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 4 | Recruiting | Anhui Provincial Cancer Hospital | 107 | 2026-07-24 | 2026-08-04 |
| Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies camrelizumab with famitinib - Head and Neck Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-07-01 | 2026-06-23 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer Camrelizumab, Famitinib Malate, Chemotherapy - Cervical Cancer | Phase 2 | Not yet recruiting | Hunan Cancer Hospital | 54 | 2026-06-30 | 2026-06-04 |
| Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer Camrelizumab, Platinum-based Chemotherapy plus PD-1 inhibitor, De-escalated Radiotherapy - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 180 | 2026-06-12 | 2026-08-28 |
| Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma Trastuzumab Rezetecan plus Camrelizumab - Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer | Phase 2 | Not yet recruiting | Sheng Tai | 44 | 2026-06-05 | 2026-06-10 |
| A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC - HCC - Hepatocellular Carcinoma | Not applicable | Not yet recruiting | Henan Cancer Hospital | 208 | 2026-05-25 | 2026-06-01 |
| Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer Short-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine - Rectal Cancer Patients | Phase 2 | Not yet recruiting | Guangdong Provincial People's Hospital | 44 | 2026-05-20 | 2026-04-13 |
| A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care - HCC | Phase 2 / Phase 3 | Recruiting | Guangzhou Virotech Pharmaceutical Co., Ltd. | 66 | 2026-05-13 | 2026-05-15 |
| Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma Becotatug Vedotin, Toripalimab, Camrelizumab - Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-04-20 | 2026-04-29 |
| Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment, A Phase II Study Ivarmacitinib + Camrelizumab + Fruquintinib - Refractory Metastatic Colorectal Cancer | Phase 2 | Recruiting | Renmin Hospital of Wuhan University | 33 | 2026-04-14 | 2026-10-26 |
| A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer Camrelizumab, famotinib - Cervical Cancer, Radical Surgery | Not applicable | Not yet recruiting | Jin LI | 30 | 2026-04-01 | 2026-03-12 |
| Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Interferon-γ, Camrelizumab - Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Hefei Cancer Hospital of the Chinese Academy of Sciences | 84 | 2026-03-20 | 2026-08-26 |
| Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy Camrelizumab + Risedronate Sodium + Chemotherapy - Breast Cancer Triple Negative Breast Cancer | Phase 2 | Active not recruiting | Harbin Medical University | 30 | 2026-03-04 | 2026-03-13 |
| Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Camrelizumab and Cetuximab, Camrelizumab and Chemotherapy - Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | Yue He, MD | 246 | 2026-02-01 | 2026-02-25 |
| A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer Camrelizumab - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Chinese PLA General Hospital | 44 | 2026-02-01 | 2026-04-14 |
Showing 20 of 465. Sign in to see all of them.
Carcinoma, Hepatocellular (41) · Carcinoma, Non-Small-Cell Lung (31) · Nasopharyngeal Carcinoma (24) · Triple Negative Breast Neoplasms (23) · Stomach Neoplasms (22) · Esophageal Neoplasms (20) · Esophageal Squamous Cell Carcinoma (20) · Breast Neoplasms (19) · Squamous Cell Carcinoma of Head and Neck (15) · Colorectal Neoplasms (13) · Uterine Cervical Neoplasms (12) · Sarcoma (10) · Lung Neoplasms (9) · Pancreatic Neoplasms (9) · Neoplasm Metastasis (8)
Jiangsu HengRui Medicine Co., Ltd. (44) · Sun Yat-sen University (41) · Fudan University (34) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (18) · Chinese PLA General Hospital (13) · Henan Cancer Hospital (13) · Peking Union Medical College Hospital (13) · Tianjin Medical University Cancer Institute and Hospital (12) · Peking University Cancer Hospital & Institute (11) · Zhejiang Cancer Hospital (10) · West China Hospital (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (7) · Ruijin Hospital (7) · Shanghai Zhongshan Hospital (7) · The First Affiliated Hospital of Zhengzhou University (7)
China (397) · Russia (2) · South Korea (2) · Australia (1) · Belgium (1) · Germany (1) · Hong Kong (1) · Italy (1) · Poland (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · Ukraine (1) · United States (1)
Feng Wang (4) · Ding Ma (3) · Feng Wang, Doctor (3) · Jun Zhang, MD & Ph. D (3) · Li Zhang, MD (3) · Qing Yang, MD (3) · Yanqiao Zhang, PhD (3) · Erwei Song, M.D., Ph.D. (2) · Jianjun Zou, MD, PhD (2) · Jieqiong Liu (2) · Jingbo Wang (2) · Lin Shen, MD (2) · Ming-Yuan Chen, MD, PhD (2) · Wei Shi, MD (2) · Ying Wang, Ph.D, M.D. (2)
PMID 30213452, PMID 41121239, PMID 30348638, PMID 32112738, PMID 32376724, PMID 32448804, PMID 37409613, PMID 37580352, PMID 15126782, PMID 15875784, PMID 17340590, PMID 18172173, PMID 18971936, PMID 20375404, PMID 20516446, PMID 21296855, PMID 21742485, PMID 22575238, PMID 23452187, PMID 23918952, PMID 24357284, PMID 24581682, PMID 24948466, PMID 25800393, PMID 25838374, PMID 25838375, PMID 26028407, PMID 26291008, PMID 26515495, PMID 26755520, PMID 26901407, PMID 27324428, PMID 27413711, PMID 27827318, PMID 27959684, PMID 28196905, PMID 28197365, PMID 28408606, PMID 28583311, PMID 28596308, PMID 28796558, PMID 28837405, PMID 29368638, PMID 29584545, PMID 29614760, PMID 29663291, PMID 30280641, PMID 30293387, PMID 30357594, PMID 30835255